Resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in
non small cell lung cancer (NSCLC) is mediated by two major mechanisms namely …

Lung cancer remains the leading cause of cancer-related death. Non-small cell lung cancer
(NSCLC) represents 85% of all lung cancer cases and it is classified into three major …

Lung cancer continues to be a major health problem and the most common cancer-related
mortality worldwide with about 80%–85% patients suffering from nonsmall cell lung cancer …

EGFR somatic mutations define a subset of NSCLCs that are most likely to benefit from
EGFR tyrosine kinase inhibitors (TKIs). These tumors are dependent on EGFR-signaling for …

The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …

Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring
epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer …

Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …

The epidermal growth factor receptor (EGFR) is a well‐characterized oncogene that is
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Introduction: The epidermal growth factor receptor (EGFR) and its family members are
involved in many aspects of tumor biological processes. Aberrant activation of the EGFR …